Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. (Q50981985)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 April 2015

Language	Label	Description	Also known as
English	Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.	scientific article published on 28 April 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

1 reference

based on heuristic

inferred from title

endometrial carcinoma

1 reference

based on heuristic

inferred from title

Diether Lambrechts

5

object named as

Diether Lambrechts

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

Frédéric Amant

6

object named as

Frédéric Amant

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

author name string

Stefanie Schrauwen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Jeroen Depreeuw

2

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Lieve Coenegrachts

3

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Els Hermans

4

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

language of work or name

0 references

publication date

28 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

138

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

1

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

165-173

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Hormonal treatment of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Markers for individualised therapy in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

PI3K inhibitors for cancer treatment: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identifiers

10.1016/J.YGYNO.2015.04.028

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50981985&oldid=1774228250"